[
    {
        "question": "How many patients in the dataset have Grade 1 gliomas?",
        "ground_truth": "487 patients have Grade 0 gliomas, and 352 patients have Grade 1 gliomas",
        "derivation": "_.countBy(data, 'Grade')",
        "type": "Information Retrieval",
        "subtype": "Direct Value Retrieval",
        "difficulty": "easy",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "352 patients in the dataset have Grade 1 gliomas."
    },
    {
        "question": "List the number of patients who have both IDH1 and TP53 mutations (where both values are 1).",
        "ground_truth": "238 patients have both IDH1 and TP53 mutations",
        "derivation": "data.filter(row => row.IDH1 === 1 && row.TP53 === 1).length",
        "type": "Information Retrieval",
        "subtype": "Conditional Retrieval and Filtering",
        "difficulty": "medium",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "238"
    },
    {
        "question": "Which genetic mutation (among all recorded mutations) appears most frequently in the dataset?",
        "ground_truth": "IDH1 is the most frequent mutation with 404 cases",
        "derivation": "Object.entries(mutationCounts).sort((a,b) => b[1] - a[1])[0]",
        "type": "Information Retrieval",
        "subtype": "Comparison and Ranking",
        "difficulty": "medium",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "IDH1"
    },
    {
        "question": "Group patients by Grade and calculate the average age at diagnosis for each grade.",
        "ground_truth": "Grade 0: 43.87 years, Grade 1: 60.70 years",
        "derivation": "_.groupBy(data, 'Grade').map(group => calculateMean(group.map(p => p.Age_at_diagnosis)))",
        "type": "Statistics",
        "subtype": "Descriptive Statistics",
        "difficulty": "medium",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "The average age at diagnosis for Grade 0 is 43.87 and for Grade 1 is 60.70."
    },
    {
        "question": "What is the probability of having an EGFR mutation given that a patient has a Grade 4 glioma?",
        "ground_truth": "31.8% (112 EGFR mutations out of 352 Grade 4 cases)",
        "derivation": "data.filter(row => row.Grade === 4 && row.EGFR === 1).length / data.filter(row => row.Grade === 4).length",
        "type": "Statistics",
        "subtype": "Probability and Risk Analysis",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "The probability of having an EGFR mutation given that a patient has a Grade 4 glioma is 0.0"
    },
    {
        "question": "What is the mean, median, and standard deviation of Age_at_diagnosis in the dataset?",
        "ground_truth": "Mean: 50.94 years, Standard Deviation: 15.69 years",
        "derivation": "const ages = data.map(row => row.Age_at_diagnosis).filter(age => age != null); calculateMean(ages); standardDeviation(ages)",
        "type": "Statistics",
        "subtype": "Descriptive Statistics",
        "difficulty": "medium",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "The mean age at diagnosis is approximately 50.94, the median age at diagnosis is 51.55, and the standard deviation of age at diagnosis is approximately 15.70."
    },
    {
        "question": "Is there a noticeable pattern in the co-occurrence of IDH1 and IDH2 mutations across different age groups?",
        "ground_truth": "There are 0 cases of co-occurrence between IDH1 and IDH2 mutations",
        "derivation": "data.filter(row => row.IDH1 === 1 && row.IDH2 === 1).length",
        "type": "Information Retrieval",
        "subtype": "Pattern and Trend Recognition",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "There is a noticeable pattern in the co-occurrence of IDH1 and IDH2 mutations across different age groups. The co-occurrence of IDH1 and IDH2 mutations decreases as age at diagnosis increases."
    },
    {
        "question": "Calculate the variance in age at diagnosis across different glioma grades.",
        "ground_truth": "IDH1-mutated variance: 149.78, IDH1-wildtype variance: 182.16",
        "derivation": "const agesByIdh1 = _.groupBy(data, 'IDH1'); standardDeviation(agesByIdh1[1]) ** 2",
        "type": "Statistics",
        "subtype": "Variance and Standard Deviation",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "The variance in age at diagnosis for Grade 0 is 175.873372 and for Grade 1 is 180.286473."
    },
    {
        "question": "Is there a correlation between EGFR mutation status and glioma grade?",
        "ground_truth": "Grade 0: 6.37% EGFR mutation rate, Grade 1: 23.01% EGFR mutation rate",
        "derivation": "const egfrByGrade = _.groupBy(data, 'Grade'); Object.entries(egfrByGrade).map(([grade, patients]) => ({grade, egfrRate: patients.filter(p => p.EGFR === 1).length / patients.length}))",
        "type": "Statistics",
        "subtype": "Correlation and Association",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "0.2415"
    },
    {
        "question": "Provide a summary of the patient population including grade distribution, gender ratio, and most common mutations.",
        "ground_truth": "Total patients: 839; Grade 0: 487, Grade 1: 352; Males in Grade 0: 271, Females in Grade 0: 216; Males in Grade 1: 217, Females in Grade 1: 135; Most common mutation: IDH1 (404 cases)",
        "derivation": "Multiple analyses combined",
        "type": "Information Retrieval",
        "subtype": "Summary and Reporting from Tables",
        "difficulty": "medium",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "The grade distribution is 0: 487, 1: 352. The gender ratio is 0: 488, 1: 351. The most common mutations are IDH1, TP53, ATRX, PTEN, and EGFR."
    },
    {
        "question": "Calculate the 95% confidence interval for the mean age at diagnosis for patients with IDH1 mutations.",
        "ground_truth": "Mean: 41.67 years, 95% CI: [40.48, 42.87] years",
        "derivation": "confidenceInterval(data.filter(row => row.IDH1 === 1).map(row => row.Age_at_diagnosis))",
        "type": "Statistics",
        "subtype": "Confidence Intervals",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "The 95% confidence interval for the mean age at diagnosis for patients with IDH1 mutations is [30.45, 34.89]"
    },
    {
        "question": "Group patients into clusters based on their mutation profiles (IDH1, TP53, ATRX, PTEN, EGFR) and analyze the characteristics of each cluster.",
        "ground_truth": "Most common patterns: No mutations (170 patients, avg age 59.94), ATRX-IDH1-TP53 (167 patients, avg age 38.41), IDH1 only (146 patients, avg age 46.38)",
        "derivation": "Complex clustering analysis of mutation patterns",
        "type": "Statistics",
        "subtype": "Classification and Clustering",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "We have grouped patients into clusters based on their mutation profiles (IDH1, TP53, ATRX, PTEN, EGFR) and analyzed the characteristics of each cluster by calculating the mean values for each feature."
    },
    {
        "question": "Analyze the trend of mutation frequencies (IDH1, TP53, ATRX) across different age groups.",
        "ground_truth": "Age <30: IDH1 (82.9%), TP53 (72.4%), ATRX (63.2%); Age 30-45: IDH1 (83.3%), TP53 (59.8%), ATRX (44.3%); Age 45-60: IDH1 (38.0%), TP53 (30.2%), ATRX (15.3%); Age 60+: IDH1 (14.9%), TP53 (26.3%), ATRX (8.0%)",
        "derivation": "Mutation frequencies calculated by age group using groupBy and frequency counts",
        "type": "Statistics",
        "subtype": "Trend Analysis and Smoothing",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "The trend of mutation frequencies (IDH1, TP53, ATRX) across different age groups is as follows:\n- Age group (14.345, 39.377]: IDH1 - 0.844538, TP53 - 0.647059, ATRX - 0.533613\n- Age group (39.377, 64.333]: IDH1 - 0.433333, TP53 - 0.350000, ATRX - 0.183333\n- Age group (64.333, 89.29]: IDH1 - 0.116022, TP53 - 0.259669, ATRX - 0.071823"
    },
    {
        "question": "Based on the mutation data, what might explain the relationship between IDH1 mutation status and patient age at diagnosis?",
        "ground_truth": "IDH1 mutated patients are significantly younger (mean 41.67 years) compared to wild-type (mean ~60 years), with different age distributions and clinical characteristics",
        "derivation": "Analysis of age distributions and confidence intervals by mutation status",
        "type": "Information Retrieval",
        "subtype": "Contextual Interpretation and Explanation",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "The relationship between IDH1 mutation status and patient age at diagnosis is that patients with IDH1 mutation tend to be diagnosed at a younger age compared to those without the mutation."
    },
    {
        "question": "What is the relationship between age, gender, and mutation patterns?",
        "ground_truth": "Males and females show different mutation frequencies: Males (Gender=0): IDH1: 46.1%, TP53: 41.4%, ATRX: 23.8%; Females (Gender=1): IDH1: 51.0%, TP53: 41.6%, ATRX: 28.8%",
        "derivation": "Analyzed gender-specific mutation rates using data grouping and frequency calculations",
        "type": "Statistics",
        "subtype": "Correlation and Association",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "The relationship between age, gender, and mutation patterns shows that while the average age at diagnosis is similar for both genders, there are differences in mutation patterns between them."
    },
    {
        "question": "Analyze the distribution of risk profiles based on mutation combinations.",
        "ground_truth": "Four risk groups identified: Low risk (404 patients, avg age 41.64), High risk (203 patients, avg age 60.89), Mixed (12 patients, avg age 41.39), No risk mutations (220 patients, avg age 59.35)",
        "derivation": "Created risk profiles based on combinations of high-risk (EGFR, PTEN) and low-risk (IDH1, CIC) mutations",
        "type": "Statistics",
        "subtype": "Classification and Clustering",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "The distribution of risk profiles based on mutation combinations has been analyzed."
    },
    {
        "question": "What are the racial differences in mutation frequencies, if any?",
        "ground_truth": "Race 0 (n=765): IDH1 49.8%, TP53 42.7%, ATRX 26.3%; Race 1 (n=59): IDH1 25.4%, TP53 30.5%, ATRX 22.0%; Race 2 (n=14): IDH1 57.1%, TP53 21.4%, ATRX 21.4%",
        "derivation": "Calculated mutation rates by racial groups using groupBy and frequency analysis",
        "type": "Information Retrieval",
        "subtype": "Multi-Column Analysis and Summarization",
        "difficulty": "medium",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "The racial differences in mutation frequencies are as follows:\n- Race 0: Mutation frequencies vary across different genes.\n- Race 1: Mutation frequencies are higher in some genes compared to Race 0.\n- Race 2: Mutation frequencies are different from Race 0 and Race 1, with some genes having higher frequencies.\n- Race 3: Mutation frequencies are all 0 for this race."
    },
    {
        "question": "Calculate the mutation burden distribution across the dataset.",
        "ground_truth": "Distribution of number of mutations per patient: 0: 124 patients, 1: 213 patients, 2: 262 patients, 3: 201 patients, 4: 35 patients, 5-7: 4 patients",
        "derivation": "Counted total number of mutations per patient and created frequency distribution",
        "type": "Statistics",
        "subtype": "Frequency and Distribution Analysis",
        "difficulty": "medium",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "The mutation burden distribution across the dataset is as follows:\n0 mutations: 1\n1 mutation: 45\n2 mutations: 189\n3 mutations: 276\n4 mutations: 202\n5 mutations: 89\n6 mutations: 37"
    },
    {
        "question": "What is the relationship between IDH1 mutation and glioma grade?",
        "ground_truth": "In Grade 0 gliomas, 381/487 (78.2%) are IDH1-mutant, while in Grade 1 gliomas, only 23/352 (6.5%) are IDH1-mutant",
        "derivation": "_.groupBy(data, 'Grade'); _.mapValues(groups, g => _.countBy(g, 'IDH1'))",
        "type": "Statistics",
        "subtype": "Correlation and Association",
        "difficulty": "medium",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "The relationship between IDH1 mutation and glioma grade is that samples with IDH1 mutation tend to have lower glioma grades compared to samples without IDH1 mutation."
    },
    {
        "question": "Is there an age difference between IDH1-mutant and IDH1-wildtype gliomas?",
        "ground_truth": "Yes, IDH1-mutant patients are significantly younger (mean age 41.7 years) compared to IDH1-wildtype patients (mean age 59.5 years)",
        "derivation": "_.groupBy(data, 'IDH1'); calculate mean age for each group",
        "type": "Statistics",
        "subtype": "Descriptive Statistics",
        "difficulty": "medium",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "Yes, there is an age difference between IDH1-mutant and IDH1-wildtype gliomas."
    },
    {
        "question": "What is the co-occurrence pattern of IDH1 and TP53 mutations?",
        "ground_truth": "Of IDH1-mutant cases, 238/404 (58.9%) have TP53 mutation. Of IDH1-wildtype cases, only 110/435 (25.3%) have TP53 mutation",
        "derivation": "_.countBy(data, row => `IDH1:${row.IDH1},TP53:${row.TP53}`)",
        "type": "Information Retrieval",
        "subtype": "Pattern and Trend Recognition",
        "difficulty": "medium",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "The co-occurrence pattern of IDH1 and TP53 mutations is 238."
    },
    {
        "question": "What is the distribution of gender in the dataset and how does it relate to mutation status?",
        "ground_truth": "There are 488 females (58.2%) and 351 males (41.8%) in the dataset",
        "derivation": "_.countBy(data, 'Gender')",
        "type": "Information Retrieval",
        "subtype": "Multi-Column Analysis and Summarization",
        "difficulty": "easy",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "The distribution of gender in the dataset is 488 entries with gender 0 and 351 entries with gender 1. Gender 0 has higher counts for mutations in genes IDH1, TP53, ATRX, PTEN, and EGFR compared to gender 1."
    },
    {
        "question": "What proportion of lower-grade (Grade 0) gliomas have IDH1 mutations?",
        "ground_truth": "Of Grade 0 gliomas, 381/487 (78.2%) have IDH1 mutations",
        "derivation": "filterByGrade(data, 0).filter(row => row.IDH1 === 1).length / filterByGrade(data, 0).length",
        "type": "Information Retrieval",
        "subtype": "Conditional Retrieval and Filtering",
        "difficulty": "medium",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "The proportion of lower-grade (Grade 0) gliomas that have IDH1 mutations cannot be calculated using the provided tools."
    },
    {
        "question": "Is there evidence of mutual exclusivity between EGFR and IDH1 mutations?",
        "ground_truth": "Yes, among 112 EGFR-mutant cases, only 4 (3.6%) have IDH1 mutations, suggesting strong mutual exclusivity",
        "derivation": "_.countBy(data, row => `EGFR:${row.EGFR},IDH1:${row.IDH1}`)",
        "type": "Information Retrieval",
        "subtype": "Pattern and Trend Recognition",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "Yes, there is evidence of mutual exclusivity between EGFR and IDH1 mutations in the dataframe."
    },
    {
        "question": "Do molecular profiles differ by patient age?",
        "ground_truth": "Yes, IDH1 mutations are significantly more common in younger patients (mean age 41.7 vs 59.5 years), suggesting distinct molecular pathways in different age groups",
        "derivation": "compare mean age between IDH1-mutant and wildtype groups",
        "type": "Statistics",
        "subtype": "Correlation and Association",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "Yes, molecular profiles differ by patient age as shown by the mean values of the molecular profiles grouped by age at diagnosis."
    },
    {
        "question": "What is the frequency of ATRX mutations in IDH1-mutant vs IDH1-wildtype gliomas?",
        "ground_truth": "Of the 217 ATRX-mutant cases in the dataset, 189 (87.1%) occur in IDH1-mutant gliomas, showing strong co-occurrence",
        "derivation": "_.countBy(data, row => `ATRX:${row.ATRX},IDH1:${row.IDH1}`)",
        "type": "Information Retrieval",
        "subtype": "Pattern and Trend Recognition",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "The frequency of ATRX mutations in IDH1-mutant vs IDH1-wildtype gliomas is 0.066667 vs 0.465347."
    },
    {
        "question": "What is the frequency of concurrent mutations in the PI3K pathway (PIK3CA, PIK3R1, PTEN)?",
        "ground_truth": "Only 3 cases (0.36%) show concurrent PIK3CA and PIK3R1 mutations, while 591 cases (70.4%) have no mutations in any of these genes",
        "derivation": "_.countBy(data, row => `PIK3CA:${row.PIK3CA},PIK3R1:${row.PIK3R1},PTEN:${row.PTEN}`)",
        "type": "Information Retrieval",
        "subtype": "Pattern and Trend Recognition",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "The frequency of concurrent mutations in the PI3K pathway (PIK3CA, PIK3R1, PTEN) is 20."
    },
    {
        "question": "Is there evidence of mutual exclusivity between PTEN and PIK3CA mutations?",
        "ground_truth": "Yes, of 141 PTEN-mutant cases, only 7 (5%) have concurrent PIK3CA mutations, suggesting mutual exclusivity in the PI3K pathway",
        "derivation": "_.countBy(data.filter(row => row.PTEN === 1), 'PIK3CA')",
        "type": "Information Retrieval",
        "subtype": "Pattern and Trend Recognition",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "Yes, there is evidence of mutual exclusivity between PTEN and PIK3CA mutations as there are no samples where both mutations are present."
    },
    {
        "question": "How does IDH1 mutation frequency vary across racial groups?",
        "ground_truth": "IDH1 mutation frequencies vary by race: Race 0 (49.8%), Race 1 (25.4%), Race 2 (57.1%), showing significant variation in molecular profiles",
        "derivation": "_.mapValues(_.groupBy(data, 'Race'), group => _.countBy(group, 'IDH1'))",
        "type": "Information Retrieval",
        "subtype": "Multi-Column Analysis and Summarization",
        "difficulty": "medium",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "The IDH1 mutation frequency varies across racial groups as follows:\n- Race 0: 49.8%\n- Race 1: 25.4%\n- Race 2: 57.1%\n- Race 3: 0.0%"
    },
    {
        "question": "Is there a difference in EGFR mutation frequency across racial groups?",
        "ground_truth": "EGFR mutation rates vary: Race 0 (12.8%), Race 1 (22.0%), Race 2 (7.1%), suggesting potential racial differences in molecular pathways",
        "derivation": "_.mapValues(_.groupBy(data, 'Race'), group => _.countBy(group, 'EGFR'))",
        "difficulty": "hard",
        "subtype": "Demographic Analysis",
        "type": "comparison",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "The mean EGFR mutation frequency for each racial group is 0.128105 for Race 0, 0.220339 for Race 1, 0.071429 for Race 2, and 0.000000 for Race 3."
    },
    {
        "question": "How does IDH1 mutation frequency vary across racial groups?",
        "ground_truth": "IDH1 mutation frequencies vary by race: Race 0 (49.8%), Race 1 (25.4%), Race 2 (57.1%), showing significant variation in molecular profiles",
        "derivation": "_.mapValues(_.groupBy(data, 'Race'), group => _.countBy(group, 'IDH1'))",
        "type": "Information Retrieval",
        "subtype": "Multi-Column Analysis and Summarization",
        "difficulty": "medium",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "The IDH1 mutation frequency varies across racial groups as follows:\n- Race 0: 49.8%\n- Race 1: 25.4%\n- Race 2: 57.1%\n- Race 3: 0.0%"
    },
    {
        "question": "Is there a difference in EGFR mutation frequency across racial groups?",
        "ground_truth": "EGFR mutation rates vary: Race 0 (12.8%), Race 1 (22.0%), Race 2 (7.1%), suggesting potential racial differences in molecular pathways",
        "derivation": "_.mapValues(_.groupBy(data, 'Race'), group => _.countBy(group, 'EGFR'))",
        "type": "Information Retrieval",
        "subtype": "Multi-Column Analysis and Summarization",
        "difficulty": "medium",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "Yes, there is a difference in EGFR mutation frequency across racial groups."
    },
    {
        "question": "What is the pattern of co-occurrence between EGFR and PDGFRA mutations?",
        "ground_truth": "Of 112 EGFR-mutant cases, only 5 (4.5%) have concurrent PDGFRA mutations, while 710 cases (84.6%) have neither mutation",
        "derivation": "_.countBy(data, row => `EGFR:${row.EGFR},PDGFRA:${row.PDGFRA}`)",
        "type": "Information Retrieval",
        "subtype": "Pattern and Trend Recognition",
        "difficulty": "medium",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "The pattern of co-occurrence between EGFR and PDGFRA mutations is that they both occur together in 5 rows of the dataframe."
    },
    {
        "question": "Are PDGFRA mutations associated with specific molecular subtypes?",
        "ground_truth": "Of 22 PDGFRA-mutant cases, 17 (77.3%) occur in EGFR-wildtype tumors, and 16 (72.7%) in IDH1-wildtype tumors, suggesting a distinct molecular subtype",
        "derivation": "analysis of PDGFRA mutants with EGFR and IDH1 status",
        "type": "Statistics",
        "subtype": "Correlation and Association",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "To determine if PDGFRA mutations are associated with specific molecular subtypes, we need to check the distribution of PDGFRA mutations across different molecular subtypes in the dataframe using the `python_repl_ast` tool."
    },
    {
        "question": "Does the IDH1-ATRX-TP53 triple-positive signature represent a distinct biological entity, and what are its clinical implications?",
        "ground_truth": "171 cases (20.4%) show triple-positive signature, with mean age 38.5 years and strong enrichment in Grade 0 (90.1% of triple-positive cases), suggesting a distinct biological subtype with better prognosis",
        "derivation": "Analysis of co-occurrence patterns and clinical features in triple-positive cases",
        "type": "Statistics",
        "subtype": "Classification and Clustering",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "The IDH1-ATRX-TP53 triple-positive signature represents a distinct biological entity with 171 samples in the dataframe `df`."
    },
    {
        "question": "How do alterations in the RTK/PI3K pathway members (EGFR, PDGFRA, PIK3CA, PIK3R1, PTEN) cooperate to drive gliomagenesis, and do they define specific molecular subtypes?",
        "ground_truth": "RTK/PI3K pathway shows distinct patterns: EGFR mutations (13.3%) are mutually exclusive with PDGFRA (2.6%), while PIK3CA/PIK3R1 mutations show limited co-occurrence with PTEN loss, suggesting different mechanisms of pathway activation",
        "derivation": "Complex pathway analysis including mutual exclusivity and co-occurrence patterns",
        "type": "Information Retrieval",
        "subtype": "Pattern and Trend Recognition",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "Use python_repl_ast to access the dataframe and check the values of the RTK/PI3K pathway members."
    },
    {
        "question": "Do the distinct molecular profiles in different age groups suggest different cellular origins or evolutionary paths in glioma development?",
        "ground_truth": "Young patients (<45 years) show enrichment for IDH1-ATRX-TP53 mutations (mean age 38.5), while older patients show EGFR/PTEN alterations (mean age 60.7), suggesting distinct developmental pathways",
        "derivation": "Integration of age patterns with molecular subtypes",
        "type": "Statistics",
        "subtype": "Classification and Clustering",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "Yes, the distinct molecular profiles in different age groups suggest different cellular origins or evolutionary paths in glioma development."
    },
    {
        "question": "How does the interplay between chromatin modifiers (ATRX, SMARCA4, BCOR) and metabolic alterations (IDH1/2) influence glioma development and progression?",
        "ground_truth": "ATRX mutations strongly co-occur with IDH1 (87.1%) but rarely with SMARCA4/BCOR, suggesting distinct chromatin-regulatory mechanisms in IDH-mutant vs wildtype gliomas",
        "derivation": "Analysis of chromatin modifier co-occurrence patterns and associations",
        "type": "Information Retrieval",
        "subtype": "Pattern and Trend Recognition",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "The correlation between chromatin modifiers (ATRX, SMARCA4, BCOR) and metabolic alterations (IDH1/2) in the dataframe is as follows:\n\n|        |   ATRX |   SMARCA4 |   BCOR |   IDH1 |   IDH2 |\n|-------:|-------:|----------:|-------:|-------:|-------:|\n| ATRX   |      1 |  -0.5     |  0.5   | -0.5   | -0.5   |\n| SMARCA4|     -0.5|   1       | -1     |  0.5   |  0.5   |\n| BCOR   |      0.5|  -1       |  1     | -0.5   | -0.5   |\n| IDH1   |     -0.5|   0.5     | -0.5   |  1     |  0.5   |\n| IDH2   |     -0.5|   0.5     | -0.5   |  0.5   |  1     |"
    },
    {
        "question": "How can the distinct molecular subtypes in glioma inform personalized treatment strategies and clinical trial design?",
        "ground_truth": "Four major molecular subtypes identified: IDH-triple (20.4%, mean age 38.5), IDH-only (19.8%, mean age 45.8), RTK/PI3K (24.8%, mean age 60.3), and Other (35%, mean age 54.4). Each shows distinct grade distributions and mutation patterns, suggesting different therapeutic vulnerabilities",
        "derivation": "Integration of molecular subtypes with clinical characteristics",
        "type": "Statistics",
        "subtype": "Classification and Clustering",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "The distinct molecular subtypes in glioma can be informed by analyzing the frequency of genetic mutations such as IDH1, TP53, ATRX, PTEN, EGFR, CIC, MUC16, PIK3CA, NF1, PIK3R1, FUBP1, RB1, NOTCH1, BCOR, CSMD3, SMARCA4, GRIN2A, IDH2, FAT4, and PDGFRA in the dataset."
    },
    {
        "question": "What do the age-specific molecular patterns reveal about glioma biology across different populations, and how should this inform screening and prevention strategies?",
        "ground_truth": "Dramatic shift in molecular profiles with age: IDH-pathway mutations dominate in young patients (<45 years, 83.3%), while RTK/PI3K alterations predominate in older patients (>60 years, 47.2%). This suggests age-specific oncogenic mechanisms requiring different prevention strategies",
        "derivation": "Analysis of age-stratified molecular patterns and risk factors",
        "type": "Information Retrieval",
        "subtype": "Pattern and Trend Recognition",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "The age-specific molecular patterns in glioma biology across different populations can be analyzed by looking at the distribution of ages in the dataset. This information can inform screening and prevention strategies by understanding how age influences the molecular patterns and potential risk factors for glioma."
    },
    {
        "question": "How do the distinct molecular subtypes suggest different evolutionary trajectories in glioma, and what are the implications for treatment resistance?",
        "ground_truth": "Mutation burden analysis shows distinct patterns: IDH-triple subtype has higher mutation burden (mean 3.2 mutations) vs RTK/PI3K subtype (mean 1.8 mutations), suggesting different genomic stability mechanisms and potential resistance pathways",
        "derivation": "Integration of mutation burden, pathway analysis, and clinical correlations",
        "type": "Statistics",
        "subtype": "Classification and Clustering",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "The distinct molecular subtypes in the 'Grade' column of the dataframe are [0]."
    },
    {
        "question": "How should molecular subtype distributions influence clinical trial design and interpretation in glioma?",
        "ground_truth": "Four distinct molecular subtypes with different ages of onset and clinical features suggest need for subtype-specific trial design: IDH-triple (young, good prognosis), RTK/PI3K (older, poor prognosis), requiring different endpoints and stratification strategies",
        "derivation": "Analysis of subtype-specific characteristics and outcomes",
        "type": "Information Retrieval",
        "subtype": "Summary and Reporting from Tables",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "The distribution of molecular subtypes, such as Grade, in glioma can influence the design and interpretation of clinical trials by ensuring that the sample sizes are representative of the different subtypes and that the results are interpreted in the context of these distributions."
    }
]